Detailed Information
Cited 9 time in 
Cited 9 time in 
Cited 9 time in
Metadata Downloads
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)
- Authors
- Kim, JY[Kim, Ji-Yeon]; Im, SA[Im, Seock-Ah]; Jung, KH[Jung, Kyung Hae]; Ro, J[Ro, Jungsil]; Sohn, J[Sohn, Joohyuk]; Kim, JH[Kim, Jee Hyun]; Park, YH[Park, Yeon Hee]; Kim, TY[Kim, Tae-Yong]; Kim, SB[Kim, Sung-Bae]; Lee, KS[Lee, Keun Seok]; Kim, GM[Kim, Gun Min]; Kim, SH[Kim, Se Hyun]; Kim, S[Kim, Seonwoo]; Ahn, JS[Ahn, Jin Seok]; Lee, KH[Lee, Kyung-Hun]; Ahn, JH[Ahn, Jin-Hee]; Park, IH[Park, In Hae]; Im, YH[Im, Young-Hyuck]; KCSG[KCSG]
- Issue Date
- Nov-2018
- Publisher
- ELSEVIER SCI LTD
- Keywords
- Metastatic breast cancer; Premenopausal; Fulvestrant; Endocrine therapy
- Citation
- EUROPEAN JOURNAL OF CANCER, v.103, pp.127 - 136
- Indexed
- SCIE
SCOPUS
- Journal Title
- EUROPEAN JOURNAL OF CANCER
- Volume
- 103
- Start Page
- 127
- End Page
- 136
- ISSN
- 0959-8049
- Abstract
- Background: We investigated the efficacy and safety of fulvestrant plus goserelin (F + G) versus anastrozole plus goserelin (A + G) in comparison with goserelin (G) alone in premenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), tamoxifen-pretreated metastatic breast cancer (MBC).
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.